NYMXF (Nymox Pharmaceutical) Total Equity: $-6.78 Mil (As of Dec. 2024)


What is Nymox Pharmaceutical Total Equity?

Nymox Pharmaceutical NYMXF Total Equity is $-6.78 Mil as of Dec. 2024.

Nymox Pharmaceutical's total equity for the quarter that ended in Dec. 2024 was $-6.78 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nymox Pharmaceutical Total Equity Historical Data

* Premium members only.

The historical data trend for Nymox Pharmaceutical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nymox Pharmaceutical Total Equity Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.15 -0.51 -0.48 -3.17 -6.78

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.88 -1.90 -3.17 -6.30 -6.78

Nymox Pharmaceutical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nymox Pharmaceutical's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=0.654-7.429
=-6.78

Nymox Pharmaceutical's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=0.654-7.429
=-6.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-6.78 Mil mean?
Nymox Pharmaceutical (NYMXF) has a Total Equity of $-6.78 Mil as of Dec. 2024. The total amount of equity as record on a company's balance sheet. View historical data for Nymox Pharmaceutical and its competitors.
Is Nymox Pharmaceutical's Total Equity too high?
Nymox Pharmaceutical's current Total Equity is $-6.78 Mil.
How does Nymox Pharmaceutical's Total Equity compare to LYRA and RNAZ?
Nymox Pharmaceutical's Total Equity of $-6.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current Total Equity is $-6.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nymox Pharmaceutical stock overvalued right now?
Nymox Pharmaceutical (NYMXF) has a current Total Equity of $-6.78 Mil. The current Total Equity is $-6.78 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current Total Equity is $-6.78 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nymox Pharmaceutical Business Description

Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.